Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-4017. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 known ✓ | P28845 | 17/20 | 1.00 |
| ▸ | IDH1 | O75874 | 3/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-4017 SCHEMBL1967884 | 1.00 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| Azd-4017 SCHEMBL1967349 | 1.00 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| SCHEMBL1969175 | 0.96 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| SCHEMBL1971049 | 0.96 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| SCHEMBL1969178 | 0.96 | HSD11B1 (1.00) | HSD11B1IDH1 | |
| Azd-4017 SCHEMBL3249702 | 0.94 | HSD11B1 (0.88) | HSD11B1IDH1 | |
| SCHEMBL2005939 | 0.93 | HSD11B1 (0.87) | HSD11B1IDH1 | |
| SCHEMBL12571260 | 0.93 | HSD11B1 (0.87) | HSD11B1IDH1 | |
| SCHEMBL2005795 | 0.92 | HSD11B1 (0.86) | HSD11B1IDH1 | |
| SCHEMBL1969653 | 0.91 | HSD11B1 (0.84) | HSD11B1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590119-B2 | (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine | UNIVERSITY OF LEEDS (GB) | 2023-02-28 | — | — | US | claimed |
| EP-4058022-A1 | (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL) ACETIC ACID FOR USE IN TREATING WOUNDS | University of Leeds (GB) | 2022-09-21 | — | — | EP | claimed |
| WO-2021180643-A1 | HSD11B1 INHIBITORS FOR USE IN IMMUNOTHERAPY AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2021-09-16 | — | — | WO | claimed |
| WO-2021094390-A1 | (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL) ACETIC ACID FOR USE IN TREATING WOUNDS | UNIVERSITY OF LEEDS (GB) | 2021-05-20 | — | — | WO | claimed |
| EP-3821892-A1 | (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL) ACETIC ACID FOR USE IN TREATING WOUNDS | University of Leeds (GB) | 2021-05-19 | — | — | EP | claimed |
| US-20210137912-A1 | (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL)ACETIC ACID FOR USE IN MEDICINE | UNIVERSITY OF LEEDS (GB) | 2021-05-13 | — | — | US | claimed |
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | claimed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | claimed |
| EP-2086939-B1 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2010-07-28 | — | — | EP | claimed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025257199-A1 | THERAPIES FOR WOUND TREATMENT | ASTRAZENECA AB (SE) | 2025-12-18 | — | — | WO | disclosed |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | SPARROW PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590119-B2 | (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine | STK17A, IL17A, MAPK15 | HSD11B1 2864/4885IDH1 1010/4885 |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885IDH1 109/4885 |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885IDH1 109/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | HSD11B1 1/4885IDH1 516/4885 |
| US-20210137912-A1 | (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL)ACETIC ACID FOR USE IN MEDICINE | STK17A, IL17A, MAPK15 | HSD11B1 2864/4885IDH1 1010/4885 |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | HSD11B1 1/4885IDH1 516/4885 |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885IDH1 1975/4885 |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, NR5A1 | HSD11B1 5/4885IDH1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.